Stanley Koch, MD
Family Medicine · Morton, ILNPI 1467436436
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Modernatx, Inc. at 52.0% of the total. Reporting peaked in 2023 at $3,418 and has fallen 80.5% since, to $666 in 2025. Among family medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 215 payments — averaging $36.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$4K
- Novartis$458
- Pfizer$386
- Amgen$307
- AbbVie$278
- AstraZeneca$224
- plus $2K from 28 others
Across 191 payments — averaging $12,202 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$919K
- Modernatx, Inc.$692K
- AbbVie$250K
- BD$232K
- Cue Health Inc.$90K
- Amgen$78K
- plus $69K from 4 others
What the payments were for
- Travel & lodging$3,39344%
- Food & beverage$4,22554%
- Education$1462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 14 | $4,040 |
| Novartis | 23 | $458 |
| Pfizer | 22 | $386 |
| Amgen | 17 | $307 |
| AbbVie(2 entities) | 12 | $278 |
| AstraZeneca | 11 | $224 |
| Kowa Pharmaceuticals America, Inc. | 12 | $201 |
| Otsuka America Pharmaceutical, Inc. | 9 | $181 |
| Boehringer Ingelheim | 9 | $176 |
| Lilly USA, LLC | 10 | $168 |
| Astellas Pharma US Inc | 4 | $160 |
| GSK | 9 | $144 |
| Novo Nordisk | 8 | $135 |
| Abbott | 5 | $106 |
| Bayer | 7 | $102 |
| Radius Health, Inc. | 4 | $77 |
| Phathom Pharmaceuticals, Inc. | 3 | $67 |
| Sunovion Pharmaceuticals Inc. | 4 | $62 |
| Johnson & Johnson | 4 | $54 |
| Merck | 4 | $49 |
| Amarin Pharma, Inc. | 3 | $42 |
| Grifols USA, LLC | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 3 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $37 |
| Valeritas, Inc. | 2 | $35 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $24 |
| Exact Sciences | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Almatica Pharma LLC | 1 | $15 |
| Eisai Inc. | 1 | $12 |
How this compares
$7,764 in reported general payments places this provider in the 95th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $56,949 |
| EliquisApixaban | 86 | $54,881 |
| XareltoRivaroxaban | 61 | $36,485 |
| OzempicSemaglutide | 37 | $33,603 |
| FarxigaDapagliflozin Propanediol | 24 | $32,902 |
| JanuviaSitagliptin Phosphate | 26 | $18,378 |
| MyrbetriqMirabegron | 41 | $16,237 |
| TradjentaLinagliptin | 13 | $7,319 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $6,744 |
| Atorvastatin Calcium | 567 | $5,562 |
| Esomeprazole Magnesium | 30 | $5,226 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $5,105 |
| Calcitonin-SalmonCalcitonin,salmon,synthetic | 51 | $4,796 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $4,678 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $4,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $176 | $64,26872 claims |
| PfizerEliquis | $386 | $54,88186 claims |
| AstraZenecaFarxiga, Symbicort | $224 | $39,64649 claims |
| Johnson & JohnsonXarelto | $54 | $36,48561 claims |
| Novo NordiskOzempic | $135 | $33,60337 claims |
| MerckJanuvia | $49 | $18,37826 claims |
| Astellas Pharma US IncMyrbetriq | $160 | $16,23741 claims |
| GSKIncruse Ellipta, Anoro Ellipta, Breo Ellipta | $144 | $14,44537 claims |
| AbbVieSynthroid | $278 | $1,38022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Morton
- Frank PhillipsChicago$1.6M
- Peter TothSterling$1.4M
- Bradley TorphyChicago$1.3M
- Jeffrey RoyceRockford$890K
- Anthony AuriemmaWestmont$788K
- Manfred ManGurnee$764K
- Barbara BellarOakbrook Terrace$599K
- Bernie RancheroAltamont$533K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.